key: cord-1036643-v0xkaq2p authors: Van Damme, Ellen; De Meyer, Sandra; Bojkova, Denisa; Ciesek, Sandra; Cinatl, Jindrich; De Jonghe, Steven; Jochmans, Dirk; Leyssen, Pieter; Buyck, Christophe; Neyts, Johan; Van Loock, Marnix title: In Vitro Activity of Itraconazole Against SARS-CoV-2 date: 2020-11-13 journal: bioRxiv DOI: 10.1101/2020.11.13.381194 sha: 981692c9c3f24040af4af740bc51754d097dd933 doc_id: 1036643 cord_uid: v0xkaq2p Background As long as there is no vaccine available, having access to inhibitors of SARS-CoV-2 will be of utmost importance. Antivirals against coronaviruses do not exist, hence global drug re-purposing efforts have been carried out to identify agents that may provide clinical benefit to patients with COVID-19. Itraconazole, an antifungal agent, has been reported to have potential activity against animal coronaviruses. Methods Using cell-based phenotypic assays, the in vitro antiviral activity of itraconazole and 17-OH itraconazole was assessed against clinical isolates from a German and Belgian patient infected with SARS-CoV-2. Results Itraconazole demonstrated antiviral activity in human Caco-2 cells (EC50 = 2.3 μM; MTT assay). Similarly, its primary metabolite, 17-OH itraconazole, showed inhibition of SARS-CoV-2 activity (EC50 = 3.6 μM). Remdesivir inhibited viral replication with an EC50 = 0.4 μM. Itraconazole and 17-OH itraconazole resulted in a viral yield reduction in vitro of approximately 2-log10 and approximately 1-log10, as measured in both Caco-2 cells and VeroE6-eGFP cells, respectively. The viral yield reduction brought about by remdesivir or GS-441524 (parent nucleoside of the antiviral prodrug remdesivir; positive control) was more pronounced, with an approximately 3 log10 drop and >4 log10 drop in Caco-2 cells and VeroE6-eGFP cells, respectively. Discussion Itraconazole and 17-OH itraconazole exert in vitro low micromolar activity against SARS-CoV-2. Despite the in vitro antiviral activity, itraconazole did not result in a beneficial effect in hospitalized COVID-19 patients in a clinical study (EudraCT Number: 2020-001243-15). Highlights Itraconazole exerted in vitro low micromolar activity against SARS-CoV-2 (EC50 = 2.3 μM) Remdesivir demonstrated potent antiviral activity, confirming validity of the assay Itraconazole has since shown no efficacy in a clinical study in hospitalized COVID-19 patients The rapid spread of the severe acute respiratory syndrome-associated coronavirus-2 (SARS-57 CoV-2) disease (COVID-19) has been declared a global pandemic. 1 Itraconazole is a member of the triazole group of broad-spectrum antifungals, 9 with a well-73 established efficacy and safety profile. [8] [9] [10] [11] [12] The primary mechanism of its antifungal action is the 74 inhibition of ergosterol biosynthesis, by acting on the oxysterol-binding protein (OSBP). [13] [14] [15] [16] 75 Since ergosterol is closely related to cholesterol, it has been suggested that also in mammalian 76 cells, itraconazole acts as a cholesterol trafficking inhibitor resulting in disruption of the 77 cholesterol-enriched membranes and thus inhibition of virus replication. 6,8,17 However, a role in 78 interferon priming has also been suggested as a contributing factor to the antiviral activity. 18 In an attempt to identify therapeutic options for treating COVID- 19 SARS-CoV-2-FFM1 (strain hCoV-19/Germany/FrankfurtFFM1/2020) was isolated from a 98 German human-case sample and cultured in Caco-2 cells, as previously described. 1, 19 99 SARS-CoV-2-Germany stocks were passaged twice in Caco-2 cells prior to storage (-80°C). Cells were incubated for 48 hours; the CPE was then visually scored by two independent 116 laboratory technicians. In addition, CPE was also assessed using a 3-(4,5-dimethylthiazol-2-yl)- As a lipophilic compound, itraconazole has high bioavailability and extensive distribution 310 throughout the lung, kidney, epidermis and brain. 9 Itraconazole is predominantly metabolized by 311 the cytochrome P450 3A4 isoenzyme system, forming many metabolites. 34, 35 The main metabolite produced is 17-OH itraconazole, which also has considerable antifungal activity. 34 SARS-CoV-2 infection in returning travelers from Wuhan, China Genomic characterisation and 353 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Genetic Recombination, 356 and Pathogenesis of Coronaviruses A novel coronavirus from patients 358 with pneumonia in China A screen of the NIH Clinical Collection small molecule library 360 identifies potential anti-coronavirus drugs Antiviral activity of itraconazole against type 1 362 feline coronavirus infection The clinically licensed 364 antifungal drug itraconazole inhibits influenza virus in vitro and in vivo Therapeutic and prophylactic activity 367 of itraconazole against human rhinovirus infection in a murine model Azole antifungal agents: emphasis on new thiazoles Itraconazole, a commonly used 372 antifungal that inhibits Hedgehog pathway activity and cancer growth Itraconazole: What clinicians should know The 381 ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus 382 fumigatus Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 384 in all biological kingdoms Itraconazole 386 inhibits enterovirus replication by targeting the oxysterol-binding protein Structure-activity 389 relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that 390 targets oxysterol-binding protein (OSBP) The cholesterol transport 392 inhibitor U18666A inhibits type 1 feline coronavirus infection The clinically licensed 395 antifungal drug itraconazole inhibits influenza virus in vitro and in vivo Development of 398 a homogeneous screening assay for automated detection of antiviral agents active against 399 severe acute respiratory syndrome-associated coronavirus Lack of 402 antiviral activity of darunavir against SARS-CoV-2 CoV-2-infected host cell reveals therapy targets Drug treatment options for the 2019-new coronavirus (2019-nCoV) Drug 408 synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and 409 itraconazole effectively impairs SARS-CoV-2 infection in vitro Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus 413 entry and infection The antiviral 417 effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry Simultaneous 420 targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR 421 signaling and angiogenesis Late 423 endosomal/lysosomal cholesterol accumulation is a host cell-protective mechanism 424 inhibiting endosomal escape of influenza A virus Limiting cholesterol 426 biosynthetic flux spontaneously engages type I IFN signaling Three-428 dimensional imaging of viral infections Membranous replication factories induced by plus-strand 430 RNA viruses Does form meet function in the coronavirus 432 replicative organelle? Endocytic pathway of feline coronavirus for cell entry: 434 differences in serotype-dependent viral entry pathway Stereospecific metabolism of 436 itraconazole by CYP3A4: Dioxoalane ring scission of azole antifungals Making sense of itraconazole pharmockinetics Covid-19: A randomized, open-label, adaptive, proof-of-concept clinical trial of 441 new antiviral drug candidates against SARS-CoV-2